UBS Group
AVNR

UBS Group’s AVANIR PHARMACEUTICALS, INC CL A AVNR Stock Holding History

UBS Group’s Portfolio AVNR Stock Details AVNR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-6,100
Closed -$103K – 10110
2014
Q4 		$103K Buy
+6,100
New +$85.8K ﹤0.01% 5681

UBS Group's AVNR Position: Q1 2015 in Review

UBS Group sold out of AVANIR PHARMACEUTICALS, INC CL A (AVNR) in Q1 2015, closing a stake of 75,541 shares — an estimated $1.28M sold.

UBS Group first reported a position in AVNR in Q4 2014 and held it in 1 quarter. The position peaked at $1.28M in Q4 2014. 0 funds tracked by Wall St. Rank hold AVNR as of Q1 2015.

  • UBS Group reported no remaining AVANIR PHARMACEUTICALS, INC CL A position as of Q1 2015 after selling out during the quarter.
  • UBS Group sold 75,541 AVANIR PHARMACEUTICALS, INC CL A shares in Q1 2015, an estimated $1.28M.
  • UBS Group first reported a position in AVANIR PHARMACEUTICALS, INC CL A in Q4 2014 and held it in 1 quarter.
  • UBS Group's AVANIR PHARMACEUTICALS, INC CL A position peaked at $1.28M in Q4 2014.
  • 0 funds tracked by Wall St. Rank held AVANIR PHARMACEUTICALS, INC CL A as of Q1 2015.

Based on UBS Group's 13F filing for Q1 2015, filed 14 May 2015.